Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for patients with chronic endocrine and neurological conditions. Its commercial portfolio includes Recorlev, a cortisol synthesis inhibitor prescribed for adults with endogenous Cushing’s syndrome who cannot undergo or have not been cured by surgery; Gvoke, a ready-to-use liquid glucagon administered for severe hypoglycemia in pediatric and adult diabetes patients; and Keveyis, a treatment for primary periodic paralysis. The company also advances development pipeline candidates such as XP-8121 for hypothyroidism and collaborates with external pharmaceutical partners using its proprietary formulation platforms.

The company focuses its commercial operations within the United States. Xeris relies on third-party contract manufacturing organizations and logistics providers across several domestic and international locations—including Illinois, Florida, California, Switzerland, and Taiwan—for product formulation, device sub-assembly, packaging, and distribution to wholesale customers and specialty pharmacies. The provided text does not state the location of the company's headquarters.

Summary of the business section of Xeris Biopharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 435 full-time employees in the United States, 216 of whom were primarily engaged in sales and marketing, 169 of whom were primarily engaged in general administration, and 50 of whom were primarily engaged in product development and research.”